Further data support the recent accelerated FDA approval of tisotumab vedotin for the treatment of recurrent or metastatic cervical cancer.
Image Credit: © PRB ARTS - www.stock.adobe.com
Tisotumab vedotin (Tivdak) administered as treatment for patients with recurrent or metastatic cervical cancer achieved a significant improvement in overall survival (OS) compared with chemotherapy, meeting the primary end point of the phase 3 innovaTV 301 clinical trial (NCT04697628).1
The OS result was determined by an Independent Data Monitoring Committee (IDMC). At the interim analysis, the IDMC found that the pre-specified threshold for OS improvement was crossed. Statistically significant improvement was also shown in the secondary end points of progression-free survival and objective response rate (ORR). Safety wise, the profile for tisotumab vedotin in the innovaTV301 study was consistent with the known profile.
“[Tisotumab vedotin] is the only United States Food and Drug Administration-approved therapy in second-line recurrent or metastatic cervical cancer regardless of biomarker status, tumor histology and prior therapy,” said Roger Dansey, MD, President of Research and Development and chief medical officer at Seagen, in a press release. “Demonstrating a survival benefit with the results of innovaTV 301 is a critical milestone in our efforts to ensure more adults living with advanced cervical cancer have an approved treatment option.”
The accelerated approval for tisotumab vedotin as treatment of recurrent or metastatic cervical cancer was granted based on the phase 2 innovaTV 204 study (NCT03438396). In the study, treatment with tisotumab vedotin led to an ORR of 24% (95% CI, 15.9%-33.3%) with complete responses in 7% of patients, partial responses in 17%, stable disease in 49%, and progressive disease in 24%. In addition, there was a 79% decrease in target lesion size from baseline observed in the study. Most patients treated with tisotumab vedotin in the innovaTV204 had quickly occurring and durable responses. The time to response was 1.4 months (range, 1.1-5.1), with responses lasting for a median of 8.3 months (range, 4.2–not reached).
Continued approval of tisotumab vedotin for recurrent or metastatic cervical cancer is contingent upon confirmatory data in the phase 3, randomized clinical trial.
In innovaTV 301, a total of 506 patients with recurrent or metastatic cervical cancer will be evaluated. Patients in the experimental arm received 2.0 mg/kg every of tisotumab vedotin, every 3 weeks. In the control arm, patients received chemotherapy of investigator’s choice, which may be one of the following.
Other end points to be explored in innovaTV 301 include time to response, duration of response, incidence of adverse events, and health-related quality of life measures.
Patients eligible for inclusion in the confirmatory study are those with recurrent or metastatic cervical cancer whose disease progressed on standard-of-care chemotherapy who have received 1 or 2 prior systemic therapy regimens for their disease, have measurable disease, an ECOG performance status of 0 or 1, and a life expectancy of at least 3 months.
“With limited options for advanced cervical cancer patients who have progressed after front-line therapy, there is a need for therapeutic options with new mechanisms of action, particularly those with a demonstrated survival benefit,” said Jan van de Winkel, PhD, chief executive officer, Genmab, in the press release. “These results provide hope for patients with recurrent or metastatic cervical cancer.”
REFERENCES:
1. Genmab and Seagen announce that Tivdak® (tisotumab vedotin-tftv) met its primary endpoint of improved overall survival in patients with recurrent or metastatic cervical cancer compared to chemotherapy. News release. Genmab A/S and Seagen, Inc. September 4, 2023. Accessed September 5, 2023. http://tinyurl.com/35h93ry7
2. Seagen and Genmab announce FDA accelerated approval for Tivdak™ (tisotumab vedotin-tftv) in previously treated recurrent or metastatic cervical cancer. News release. Seagen, Inc. September 20, 2021. Accessed September 5, 2023. https://bit.ly/3AE9bgC
3. Tisotumab vedotin vs chemotherapy in recurrent or metastatic cervical cancer (innovaTV 301). ClinicalTrials.gov. Updated August 29, 2023. Accessed September 5, 2023. http://tinyurl.com/3fzup7r5
Tisotumab Vedotin Shows Potential in Cervical Cancer With Disease Progression
October 27th 2023In an interview with Targeted Oncology, Brian Slomovitz, MD, details findings from the innovaTV 301 trial investigating tisotumab vedotin for the treatment of recurrent or metastatic cervical cancer.
Read More
Induction Chemotherapy Before Chemoradiation Betters Survival in Locally Advanced Cervical Cancer
October 23rd 2023Data presented at the 2023 ESMO Congress and showed that induction chemotherapy followed by chemoradiation reduced the risk of progression or death by 35% vs chemoradiation alone in patients with cervical cancer.
Read More
Pembrolizumab/Chemoradiotherapy Shows Clinically Meaningful PFS Improvement in Cervical Cancer
October 20th 2023Data from the KEYNOTE-A18 trial support the addition of pembrolizumab to chemoradiotherapy, which has been in place as standard of care for patients with newly diagnosed, previously untreated, high-risk locally advanced cervical breast cancer since 1999.
Read More
PDS0101 and CRT Displays Encouraging Early Data in Cervical Cancer
October 4th 2023Midway through the IMMUNOCERV trial, PDS0101 enhances the production of versatile CD8 killer T cells, leading to reduced tumor DNA and significant tumor shrinkage of over 60% in all patients with high-risk cervical cancer.
Read More